Authors

Latest:

Dr. You on Findings from the TROPHIMMUN Study in Gestational Trophoblastic Tumors

Benoit You, MD, PhD, discusses the findings of the phase 2 TROPHIMMUN study which treated chemotherapy-resistant gestational trophoblastic tumors with avelumab.

Bernard A. Fox, PhD

Latest:

Dr Fox on a Dark Matter–Containing Multivalent Vaccine in Head and Neck Cancer

Bernard A. Fox, PhD, discusses an off-the-shelf multivalent vaccine that contains cancer’s dark matter combined with anti–PD-1 and anti-GITR antibodies in head and neck cancer.

Bernard H. Bochner, MD, FACS

Latest:

Dr Bochner on the Need for Multimodal Approaches in MIBC

Bernard H. Bochner, MD, FACS discusses genomic complexity and heterogeneity in bladder cancer tumors.

Bernard J. Escudier, MD

Latest:

Dr. Escudier on Patients Preferring Pazopanib for mRCC

Dr. Bernard Escudier, from the Institut Gustave Roussy, on Patients Preferring Pazopanib for Metastatic Renal Cell Carcinoma.

Bernardo L. Rapoport, MD

Latest:

Dr. Rapoport on Rolapitant for the Prevention of CINV

Bernardo L. Rapoport, MD, chief medical oncologist, The Medical Oncology Center of Rosebank, Johannesburg, South Africa, discusses the utility of rolapitant for preventing chemotherapy-induced nausea and vomiting (CINV).

Bernd Kasper, MD, PhD

Latest:

Dr Kasper on the FDA Approval of Nirogacestat in Desmoid Tumors

Bernd Kasper, MD, PhD, discusses the significance of the FDA approval of nirogacestat for patients with desmoid tumors.

Bert H. O'Neil, MD

Latest:

Dr. O'Neil on Next Steps for Napabucasin With FOLFIRI and Bevacizumab in CRC

Bert O’Neil, MD, the Joseph W. and Jackie J. Cusick Professor of Oncology, professor of medicine, and director of the Phase I and Gastrointestinal Oncology Programs at Indiana University, discusses the next steps for napabucasin with FOLFIRI and bevacizumab (Avastin) as treatment for patients with colorectal cancer.

Bert H. ONeil, MD, Indiana University School of Medicine

Bert O'Neil

Latest:

Dr. O'Neil on Left-Sided Versus Right-Sided CRC

Bert O'Neil, MD, the Joseph W. and Jackie J. Cusick Professor of Oncology, professor of medicine, and director of the Phase I and Gastrointestinal Oncology Programs at Indiana University, discusses left-sided versus right-sided colorectal cancer (CRC).

Bert O'Neil, MD

Latest:

Dr. O'Neil on Neuroendocrine Tumors

Bert O’Neil, MD, the Joseph W. and Jackie J. Cusick Professor of Oncology, professor of medicine, and director of the Phase I and Gastrointestinal Oncology Programs at Indiana University, discusses the importance of differentiating between neuroendocrine tumors (NETs).

Bertram Yuh, MD

Latest:

Dr Yuh on the Role of Genetic Factors in Risk Stratification for Prostate Cancer

Bertram Yuh, MD, MISM, MSHCPM, discusses the role of genetic factors, such as BRCA mutations, in the risk stratification of patients with prostate cancer.

Bertrand Tombal, MD, PhD, Cliniques Universitaires Saint-Luc

Latest:

Dr Tombal on the Pharmacokinetics of Darolutamide Plus Docetaxel in mHSPC

Bertrand Tombal, MD, PhD, discusses the pharmacokinetics of darolutamide plus docetaxel in metastatic hormone-sensitive prostate cancer.

Beth DuPree, MD

Latest:

Dr. DuPree Provides Z11 Trial Takeaway Points

Dr. Beth DuPree from Holy Redeemer Health System Provides Z11 Trial Takeaway Points

Beth Eaby-Sandy, CRNP, OCN, University of Pennsylvania

Beth Fand Incollingo

Latest:

Sotorasib Shows Encouraging Antitumor Activity in Advanced NSCLC

The investigational drug sotorasib demonstrated promising antitumor activity in patients with non-small cell lung cancer that harbor the KRAS p.G12C mutation, an aberration for which no targeted treatment has yet been approved.

Beth Gilbert

Latest:

Essential Components of Survivorship Care

At the 2012 NCCN annual meeting, a panel of oncology nurses discussed the essential components of healthcare for survivors, challenges survivors face, and survivorship program models.

Beth Incollingo

Latest:

Genes Predispose Some Anthracycline Patients to Heart Failure

Researchers have identified a genetic profile of the patients who are most likely to develop congestive heart failure after being treated with anthracyclines and then undergoing hematopoeitic stem cell transplant (HCT) for a range of blood cancers.

Beth Overmoyer, MD

Latest:

Dr. Overmoyer on Inflammatory Triple-Negative Breast Cancer

Beth Overmoyer, MD, director, Inflammatory Breast Cancer Program, Dana-Farber Cancer Institute, speaks on treatment challenges of inflammatory breast cancer.

Beth Y. Karlan MD

Latest:

Dr. Karlan on Current Research Evaluating PARP Inhibitor Combination Therapy in Ovarian Cancer

Beth Y. Karlan, MD, discusses the current landscape of research investigating the efficacy of PARP inhibitor combination therapies for the treatment of patients with ovarian cancer.

Bethany Anderson, MD

Latest:

MRI-Guided Radiation Therapy Modernizes Breast Conservation Methods

The major advance of the MRI-guided radiotherapy system is the ability to visualize the lumpectomy cavity before and during the delivery of each treatment.